Population pharmacokinetics of moxifloxacin, cycloserine, p -aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis
Saved in:
| Title: | Population pharmacokinetics of moxifloxacin, cycloserine, p -aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis |
|---|---|
| Authors: | Jongsun Park, Min Jung Chang, Eun Sun Kim, Choon Taek Lee, Jung-woo Chae, Junghan Song, Ho Il Yoon, Yeon Joo Lee, Hwi-yeol Yun, Kyoung Un Park, Young Jae Cho, Jae Ho Lee, Byunghak Jin |
| Contributors: | Others, Min Jung Chang, Byunghak Jin, Jung-Woo Chae, Hwi-Yeol Yun, Eun Sun Kim, Yeon Joo Lee, Young-Jae Cho, Ho Il Yoon, Choon-Taek Lee, Kyoung Un Park, Junghan Song, Jae-Ho Lee, Jong Sun Park |
| Source: | International Journal of Antimicrobial Agents. 49:677-687 |
| Publisher Information: | Elsevier BV, 2017. |
| Publication Year: | 2017 |
| Subject Terms: | Adult, Male, 0301 basic medicine, Antitubercular Agents, Injections, Intramuscular, Injections, Plasma, 03 medical and health sciences, 0302 clinical medicine, Models, Tandem Mass Spectrometry, Second-line anti-tuberculosis drugs, Tuberculosis, Multidrug-Resistant, 80 and over, Tuberculosis, Multidrug-Resistant / drug therapy, Humans, Population pharmacokinetics, Prospective Studies, Multi-drug-resistant tuberculosis, Aged, Aged, 80 and over, Intramuscular, Chromatography, Models, Statistical, Antitubercular Agents / administration & dosage, Statistical, Middle Aged, Antitubercular Agents / pharmacokinetics, United States, 3. Good health, Plasma / chemistry, Female |
| Description: | Control of multi-drug-resistant tuberculosis (MDR-TB) requires extensive, supervised chemotherapy because second-line anti-TB drugs have a narrower therapeutic range than first-line drugs. This study aimed to develop population pharmacokinetic (PK) models for second-line drugs in patients with MDR-TB, evaluate the recommended dosage regimens and, if necessary, suggest new dosage regimens. A prospective, single-centre PK study was performed on second-line anti-TB drugs in patients with MDR-TB. Moxifloxacin, cycloserine, p-aminosalicylic acid (PAS), kanamycin and other second-line drugs were administered to the patients. Plasma concentrations were analysed using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Population PK models were developed using non-linear mixed effect modelling (NONMEM, Version 7.30; ICON Development Solutions, Ellicott City, MD, USA). Simulations were performed using the calculated PK parameters. The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin. The simulations showed that the following dosage regimens were more likely to be within the recommended concentration ranges than the raw data in this study: 200 mg of moxifloxacin once daily (QD) (patient weight |
| Document Type: | Article |
| Language: | English |
| ISSN: | 0924-8579 |
| DOI: | 10.1016/j.ijantimicag.2017.01.024 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/28408267 https://www.ncbi.nlm.nih.gov/pubmed/28408267 https://yonsei.pure.elsevier.com/en/publications/population-pharmacokinetics-of-moxifloxacin-cycloserine-p-aminosa https://www.cabdirect.org/cabdirect/abstract/20173249557 https://pubag.nal.usda.gov/catalog/5672265 https://snucm.elsevierpure.com/en/publications/population-pharmacokinetics-of-moxifloxacin-cycloserine-p-aminosa https://www.sciencedirect.com/science/article/abs/pii/S0924857917301115 |
| Rights: | Elsevier TDM CC BY NC ND |
| Accession Number: | edsair.doi.dedup.....76f18788a57a657311df3048ab39264c |
| Database: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Control of multi-drug-resistant tuberculosis (MDR-TB) requires extensive, supervised chemotherapy because second-line anti-TB drugs have a narrower therapeutic range than first-line drugs. This study aimed to develop population pharmacokinetic (PK) models for second-line drugs in patients with MDR-TB, evaluate the recommended dosage regimens and, if necessary, suggest new dosage regimens. A prospective, single-centre PK study was performed on second-line anti-TB drugs in patients with MDR-TB. Moxifloxacin, cycloserine, p-aminosalicylic acid (PAS), kanamycin and other second-line drugs were administered to the patients. Plasma concentrations were analysed using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Population PK models were developed using non-linear mixed effect modelling (NONMEM, Version 7.30; ICON Development Solutions, Ellicott City, MD, USA). Simulations were performed using the calculated PK parameters. The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin. The simulations showed that the following dosage regimens were more likely to be within the recommended concentration ranges than the raw data in this study: 200 mg of moxifloxacin once daily (QD) (patient weight |
|---|---|
| ISSN: | 09248579 |
| DOI: | 10.1016/j.ijantimicag.2017.01.024 |